<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4090">
  <stage>Registered</stage>
  <submitdate>26/10/2012</submitdate>
  <approvaldate>26/10/2012</approvaldate>
  <nctid>NCT01719263</nctid>
  <trial_identification>
    <studytitle>Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study</studytitle>
    <scientifictitle>Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSP-1570</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Emphysema</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - InterVapor® treatment plus Optimal Medical Therapy
Other interventions - Optimal Medical Therapy

Experimental: Treatment plus Optimal Medical Therapy - Patients will be treated with the InterVapor System and Optimal Medical Therapy

Active Comparator: Optimal Medical Therapy - Patients will be treated according to Optimal Medical Therapy


Treatment: devices: InterVapor® treatment plus Optimal Medical Therapy
Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).

Other interventions: Optimal Medical Therapy
Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Forced expiratory volume in 1-second (FEV1) compared to active comparator</outcome>
      <timepoint>Year 1</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of Life (SGRQ)</outcome>
      <timepoint>Year 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Responder rate for FEV1 % difference from baseline</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responder rate SGRQ pts difference from baseline</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responder rate 6MWD meter difference from baseline</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lobar Volume Reduction HRCT</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Heterogeneous emphysema with upper lobe predominance in both lungs

          -  FEV1 between 20% and 45% predicted

          -  Residual volume (RV) &gt; 150% predicted

          -  Post-rehabilitation 6-minute walk test &gt; 140 meters</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  More than 3 COPD related hospitalizations requiring antibiotics in past 12 months

          -  FEV1 &lt; 20% predicted

          -  DLCO &lt; 20% predicted or immeasurable DLCO

          -  Body mass index (BMI) &lt; 18kg/m2 or &gt; 32 kg/m2

          -  History of any of the following:

               -  Left ventricular ejection fraction (EF) = 40%

               -  Stroke

               -  Myocardial infarction or acute coronary syndrome in previous year

               -  Hospitalization due to left ventricular failure in previous 3 years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>69</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Prince Charles Hospital - Chermside</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>4032 - Chermside</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gauting</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gerlingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hemer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nuernberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Uptake Medical Corp</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to demonstrate safety and efficacy in patients with severe upper lobe
      predominant emphysema. For validity of the study, the results will be compared to patients
      that receive optimal medical therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01719263</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Felix JF Herth, MD</name>
      <address>Heidelberg University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>